SYMBIONâ„¢ ğŸ§¬
Ingestible Gut-Brain Computer Interface
Universal Health Solutions for All Humanity

ğŸŒ Mission
Symbion democratizes advanced medical diagnostics by providing continuous gut-brain axis monitoring through an affordable, non-invasive ingestible sensor. Our mission: compress global health disparities and enable preventive care for 4+ billion people in low- and middle-income countries.
ğŸ¯ What is Symbion?
Symbion is the world's first ingestible gut-brain computer interface designed from first principles to:

Monitor Root Causes: Track chronic inflammation, metabolic dysfunction, and gut-brain axis disruptionâ€”the fundamental drivers of dozens of chronic diseases
Enable Early Detection: Catch inflammatory bowel disease, depression, metabolic disorders, and neurodegenerative conditions before they become irreversible
Ensure Global Access: Engineered for <$5/unit cost at scale with infrastructure independence for LMIC deployment

Core Innovation
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  Standard Pharmaceutical Capsule (7mm Ã— 25mm)               â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  â”‚
â”‚  â”‚ Multi-Analyte Sensors: Serotonin, Dopamine, GABA,    â”‚  â”‚
â”‚  â”‚ Inflammatory Markers, pH, Temperature                  â”‚  â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤  â”‚
â”‚  â”‚ Processing: Ultra-low-power microcontroller + AI      â”‚  â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤  â”‚
â”‚  â”‚ Communication: BLE 5.0 â†’ Smartphone (Real-time data)  â”‚  â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤  â”‚
â”‚  â”‚ Power: Glucose biofuel cell (Self-powered from gut)   â”‚  â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜  â”‚
â”‚  Biocompatible Encapsulation: PLA/PGA copolymer           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
ğŸ“š Repository Structure
symbion/
â”œâ”€â”€ 00_Symbion_Master_Index_Executive_Summary.docx
â”‚   â””â”€â”€ Strategic overview, market opportunity, call to action
â”‚
â”œâ”€â”€ 01_Symbion_Technical_Specifications.docx
â”‚   â””â”€â”€ System architecture, BOM, manufacturing, software, regulatory
â”‚
â”œâ”€â”€ 02_Symbion_Benchmark_Validation_Matrix.docx
â”‚   â””â”€â”€ Analytical performance, operational specs, safety standards
â”‚
â”œâ”€â”€ 03_Symbion_Clinical_Development_Roadmap.docx
â”‚   â””â”€â”€ 60-month pathway: Foundation â†’ Validation â†’ Clinical â†’ Global Access
â”‚
â”œâ”€â”€ 04_Symbion_Global_Health_Equity_Guide.docx
â”‚   â””â”€â”€ LMIC strategy, cost engineering, partnerships, tiered pricing
â”‚
â”œâ”€â”€ 05_Symbion_Universal_Health_Integration.docx
â”‚   â””â”€â”€ First-principles root cause analysis, one-time diagnostics vision
â”‚
â”œâ”€â”€ 06_Symbion_Reference_Bibliography.docx
â”‚   â””â”€â”€ 60+ peer-reviewed citations, regulatory standards, technical sources
â”‚
â””â”€â”€ README.md
    â””â”€â”€ This file
ğŸš€ Key Features
Technical Capabilities
FeatureSpecificationBiomarkersSerotonin (10nM-10Î¼M), Dopamine (50nM-5Î¼M), GABA (100nM-50Î¼M), pH (1.0-9.0), Temperature (25-42Â°C), Inflammatory markersOperational Lifetimeâ‰¥48 hours continuous sensingWireless Range10 meters through tissue (BLE 5.0)PowerGlucose biofuel cell OR biocompatible batterySafetyISO 10993 biocompatibility, FDA Class III pathwayCost Target<$5 LMIC / $149 HIC (tiered pricing)
Clinical Applications

Inflammatory Bowel Disease (IBD): Flare prediction, treatment optimization, reducing endoscopy burden
Irritable Bowel Syndrome (IBS): Objective differentiation from organic GI disease
Depression & Anxiety: Gut-brain axis contribution assessment before pharmacotherapy
Metabolic Disorders: Pre-diabetic detection, dietary intervention monitoring
Neurodegenerative Diseases: Early prodromal detection (Parkinson's, Alzheimer's)

ğŸ“Š Market Opportunity
MetricValueGlobal IBD Prevalence6.8 million patientsDepression Burden2+ billion affected globallyDiagnostic Gap2-5 year delay in LMICs vs. 6-12 months in HICsMarket Size$12B gut health diagnostics by 2030Addressable Population4+ billion people in LMICs
ğŸ›¤ï¸ Development Roadmap
Phase 1: Foundation (Months 1-12) - $3-5M

âœ… Sensor array design finalization
âœ… Biocompatibility testing (ISO 10993)
âœ… Quality management system (ISO 13485)
âœ… Prototype development (n=50 alpha units)

Phase 2: Validation (Months 13-24) - $8-12M

ğŸ”„ Swine model studies (n=12 animals)
ğŸ”„ FDA IDE submission
ğŸ”„ Early Feasibility Study (n=15-20 patients)
ğŸ”„ Mobile app MVP development

Phase 3: Clinical Trials (Months 25-48) - $25-35M

ğŸ“… Pivotal RCT (n=300 patients, 12 sites)
ğŸ“… FDA PMA submission (Month 44)
ğŸ“… CE Marking application (Month 45)
ğŸ“… Regulatory approvals expected (Month 50-51)

Phase 4: Global Access (Months 49-60) - $15-20M

ğŸ“… WHO prequalification (Month 57)
ğŸ“… LMIC manufacturing partnerships (SEA, Africa, LATAM)
ğŸ“… Global health organization partnerships (Gavi, PATH, UNICEF)
ğŸ“… Target: 10M+ users globally

Legend: âœ… Complete | ğŸ”„ In Progress | ğŸ“… Planned
ğŸŒ Global Health Equity Strategy
Design for Equity Principles

Cost Engineering: <$5/unit through regional manufacturing and component optimization
Infrastructure Independence: No hospital, electricity, internet, or cold chain required
Technology Accessibility: Works with Android 8.0+ smartphones OR feature phones via SMS
Multilingual Support: 50+ languages with pictographic instructions
Community Health Worker Deployment: 30-minute training, no medical expertise needed

Tiered Pricing Model
Market TierCountriesPrice/UnitRationaleTier 1USA, Germany, Japan$149R&D recovery, subsidizes global accessTier 2China, Brazil, Turkey$49Volume-based pricingTier 3India, Philippines, Kenya$15At-cost + minimal marginTier 4Haiti, DRC, Afghanistan$3-5Fully subsidized by Tier 1Tier 5Humanitarian crisesFREEDonated via MSF, WHO, UNICEF
Financial Sustainability: Tier 1-2 sales (30% volume) generate 95% of revenue, enabling Tier 3-5 access (70% volume).
ğŸ“ˆ Expected Impact
5-Year Targets (Post-Approval)
MetricTargetGlobal Users50 millionLMIC Market Share70% of total usersDiagnostic Delay Reduction2-5 years â†’ <1 month in LMICsIBD Complication Prevention30% reduction in preventable hospitalizationsHealthcare Cost Savings$500-1000 per user annuallyQALYs Gained0.5-1.0 per user over 5 years
ğŸ§ª Scientific Foundation
Symbion addresses three root causes that drive multiple diseases simultaneously:

Chronic Inflammation: Links to heart disease, cancer, diabetes, neurodegenerationâ€”gut is primary source via intestinal permeability and microbiome dysbiosis
Metabolic Dysfunction: Gut-derived metabolites regulate glucose homeostasis; early detection enables pre-diabetic intervention
Gut-Brain Axis Disruption: 90% of serotonin, 50% of dopamine produced in gut; dysregulation drives depression, anxiety, Parkinson's, autism

Key Biomarkers Measured

Neurotransmitters: Serotonin, dopamine, GABA
Inflammatory: Calprotectin analogs, pH shifts, temperature
Metabolic: Glucose, short-chain fatty acids
Barrier Integrity: Permeability markers, pH gradients

ğŸ›ï¸ Regulatory Pathway
RegionClassificationPathwayTimelineUnited StatesClass IIIPMA (Premarket Approval)Month 44 submission â†’ Month 50 approvalEuropeClass IIbCE Marking (MDR 2017/745)Month 45 application â†’ Month 51 certificateGlobalN/AWHO PrequalificationMonth 52-57 review â†’ UN procurement
Precedents: Abilify MyCite (FDA-approved digital pill), PillCam (ingestible endoscopy), SetPoint VNS
ğŸ¤ Partnership Opportunities
We're Seeking Partners For:
1. Investment Partners ($50-70M total)

Series A: Phase 1-2 ($15M)
Series B: Phase 3 ($40M)
Series C: Scale-up ($15M)

2. Manufacturing Partners

MEMS sensor fabrication (biocompatible capabilities)
Medical device contract manufacturers (ISO 13485 certified)
Regional manufacturing in Southeast Asia, Sub-Saharan Africa, Latin America

3. Clinical Trial Sites

Academic medical centers with IBD/gastroenterology specialty
LMIC research institutions for field validation

4. Global Health Organizations

WHO, Gavi, PATH, UNICEF, MSF
Tiered pricing negotiation and advance market commitments

5. Technology Partners

Wireless power transfer optimization
Glucose biofuel cell development
AI/ML for biomarker analysis

ğŸ“ Contact
Zuupâ„¢ Innovation Lab
A Division of Visionblox LLC
Director: Khaalis
Email: symbion@visionblox.com
Location: Huntsville, Alabama, USA

ğŸ“„ Documentation
All framework documents are professional-grade Word files ready for:

Investor presentations and due diligence
Regulatory submissions (FDA, EMA, WHO)
Partnership negotiations
Academic collaboration

Total Documentation: 94KB across 7 comprehensive documents
ğŸ”¬ Scientific Rigor
This framework is grounded in 60+ peer-reviewed scientific publications including:

Gut-Brain Axis: Cryan et al. (2019) Physiological Reviews, Yano et al. (2015) Cell
Inflammaging: Furman et al. (2019) Nature Medicine, Franceschi et al. (2018) Nature Reviews Endocrinology
Ingestible Sensors: Mimee et al. (2018) Science, Kalantar-Zadeh et al. (2017) ACS Sensors
Global Health Equity: GBD 2019 Collaborators The Lancet, Howitt et al. (2012) The Lancet

See 06_Symbion_Reference_Bibliography.docx for complete citations.
âš–ï¸ Regulatory Compliance
Framework adheres to:

FDA 21 CFR Part 820 (Quality System Regulation)
ISO 10993 (Biocompatibility)
ISO 13485 (Medical Device QMS)
ISO 14971 (Risk Management)
IEC 60601-1 (Electrical Safety)
IEC 62304 (Software Life Cycle)
HIPAA & GDPR (Data Privacy)

ğŸ“ Academic Foundations
Developed by: Zuupâ„¢ Innovation Lab | Visionblox LLC
Principal Investigator: Khaalis (MBA Candidate, Southern New Hampshire University)
Expertise Domains:

Federal IT modernization & GSA contracting
AI integration & cloud migration
Healthcare technology & compliance systems
Global health equity & LMIC deployment strategies

ğŸŒŸ Vision

"When a subsistence farmer in rural India has access to gut-brain diagnostics rivaling what's available at Mayo Clinic. When we detect inflammatory bowel disease in Kinshasa as early as we do in Copenhagen. When mental health conditions rooted in gut-brain dysfunction are caught in their prodrome, not after years of suffering. That is when we will have truly opened the door to solving disease for all humanity."

ğŸ“œ License
Proprietary - All Rights Reserved
Copyright Â© 2025 Visionblox LLC | Zuupâ„¢ Innovation Lab
This framework and all associated intellectual property are proprietary to Visionblox LLC. Unauthorized reproduction, distribution, or use is strictly prohibited. For licensing inquiries, contact symbion@visionblox.com.

ğŸš¨ Call to Action
The technology is within reach. The regulatory pathways exist. The partnerships are forming. All that remains is the will to prioritize equity over profit maximizationâ€”to build a future where advanced medical diagnostics are a global public good, not a luxury commodity.
For Investors
Opportunity to capture $12B+ gut health diagnostics market while creating transformative global health impact.
For Regulatory Partners
Chance to pioneer gut-brain diagnostic approval pathways enabling next generation of ingestible sensors.
For Global Health Organizations
Tool to compress diagnostic disparities and enable preventive care in resource-limited settings.
For Patients
Empowerment through continuous biomarker monitoring and AI-driven personalized health insights.

Symbion: Universal gut-brain health for all humanity. Not some. All.

Last Updated: November 2025 | Version 1.0
